Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genscript Biotech ( (HK:1548) ) has shared an update.
Legend Biotech, an associate of GenScript Biotech, announced promising five-year survival data from the CARTITUDE-1 study for its CARVYKTI® therapy in treating multiple myeloma. The data, presented at the 2025 ASCO Annual Meeting, showed that one-third of patients remained progression-free for five years, highlighting the therapy’s potential impact on long-term cancer treatment. Additionally, preliminary results from ongoing studies in solid tumors were also presented, indicating potential advancements in lung and gastric cancer therapies.
More about Genscript Biotech
GenScript Biotech Corporation is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It is associated with Legend Biotech Corporation, which is listed on the Nasdaq Global Select Market in the United States. The company focuses on developing innovative biotechnological solutions, particularly in the field of cancer treatment.
Average Trading Volume: 19,473,417
Technical Sentiment Signal: Hold
Current Market Cap: HK$26.92B
See more data about 1548 stock on TipRanks’ Stock Analysis page.